- Home
- GFR vs FULC Comparison
GFR vs FULC Comparison
Compare GFR & FULC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GFR | FULC |
|---|---|---|
| Founded | 2018 | 2015 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 655.9M | 687.4M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | GFR | FULC |
|---|---|---|
| Price | $5.38 | $10.86 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $16.38 |
| AVG Volume (30 Days) | 150.4K | ★ 831.0K |
| Earning Date | 03-13-2026 | 02-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 252.40 | N/A |
| EPS | ★ 1.37 | N/A |
| Revenue | ★ $470,838,329.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $3.93 | ★ N/A |
| Revenue Growth | N/A | ★ 2752.05 |
| 52 Week Low | $3.81 | $2.32 |
| 52 Week High | $6.92 | $15.74 |
Technical Indicators
Market Signals| Indicator | GFR | FULC |
|---|---|---|
| Relative Strength Index (RSI) | 65.53 | 49.80 |
| Support Level | $4.85 | $9.78 |
| Resistance Level | $5.23 | $11.01 |
| Average True Range (ATR) | 0.23 | 0.80 |
| MACD | 0.06 | 0.04 |
| Stochastic Oscillator | 97.12 | 74.48 |
Price Performance
Historical ComparisonAbout GFR Greenfire Resources Ltd.
Greenfire Resources Ltd explores, acquires, develops and produces oil and gas in the Canadian energy sector and internationally. Greenfire currently has two producing oil sand assets, Hangingstone Expansion and Hangingstone Demo. The Company has one reportable operating segment which is made up of its oil sands operations based on geographic location : Athabasca oil sands region of Alberta, Canada, nature of the products sold and integration of facilities and operations.
About FULC Fulcrum Therapeutics Inc.
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.